as well as Alphabet. Isomorphic's technology platform has already generated a number of AI models that are being applied to the discovery of new medicines, and it already counts Eli Lilly and ...

The head of Google discusses the next AI platform shift and how it could change how we use the internet forever.

Google parent Alphabet has drawn on its DeepMind artificial intelligence division to form a drug discovery unit that it calls Isomorphic Labs. The UK-registered company will be able to tap into ...

Recursion Pharmaceuticals RXRX and Schrodinger SDGR are pioneering the use of artificial intelligence (AI) in drug discovery ...

Artificial intelligence is gaining ground in healthcare, and tech's biggest players are racing to stake their claims.

Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed ...

Alphabet remains a compelling investment due to its dominant digital advertising position, limited China exposure, and strong service-based business model. Recent earnings exceeded expectations ...

Alphabet stock is down roughly 15% in 2025. The tech giant continues to grow its search and advertising businesses, but possible setbacks loom large. Management recently announced its first-ever ...

Alphabet's dominance in search, mobile OS, and YouTube creates a powerful ecosystem with strong network effects and a significant competitive moat. AI and cloud computing offer massive growth ...